Canada markets closed

TLRY Jan 2023 5.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.7300+0.0800 (+12.31%)
As of 03:20PM EDT. Market open.
Full screen
Previous Close0.6500
Open0.6800
Bid0.6800
Ask0.7500
Strike5.00
Expire Date2023-01-20
Day's Range0.6800 - 0.8000
Contract RangeN/A
Volume827
Open Interest28.25k
  • Zacks

    Is Most-Watched Stock Tilray Brands, Inc. (TLRY) Worth Betting on Now?

    Zacks.com users have recently been watching Tilray Brands, Inc. (TLRY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

  • Motley Fool

    This Is the Boldest Prediction Yet From Tilray's CEO

    Tilray Brands (NASDAQ: TLRY) CEO Irwin Simon is no stranger to making lofty projections. Simon's goal to hit $4 billion in annual revenue assumes that legalization takes place in Europe and the U.S. And in a recent interview with CNBC, he said that once that happens, there won't be another company out there "that will have the assets and the ability to grow and build brands like we will." Tilray also has convertible notes in multi-state marijuana operator MedMen Enterprises that it could seek to convert and take a stake in once legalization takes place (currently it would run into issues owning a stake in the business given the federal ban on pot in the U.S.).

  • Motley Fool

    Why Tilray, Canopy, and Aurora Cannabis Just Jumped

    After tumbling on Friday following a lousy earnings report from Canopy Growth (NASDAQ: CGC), shares of fellow Canadian marijuana stocks Tilray (NASDAQ: TLRY) and Aurora Cannabis (NASDAQ: ACB) -- and Canopy Growth, too -- are rebounding sharply today. As of 11:30 a.m. ET, Tilray shares are gaining 10.2%, Aurora is up 12.3%, and Canopy Growth is doing best of all, jumping 16.4%. The opposite is more accurate, with investment bank Piper Sandler coming out with a lower price target on Canopy -- $2.50 per share, down from $3 previously -- and an underweight rating to boot.